Welcome to our dedicated page for Cardiol Therapeu news (Ticker: CRDL), a resource for investors and traders seeking the latest updates and insights on Cardiol Therapeu stock.
News about Cardiol Therapeutics Inc. (CRDL) centers on its progress as a clinical-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for heart disease. Headlines frequently highlight updates from the company’s key clinical programs, including the MAVERIC Program in recurrent pericarditis and the ARCHER trial in acute myocarditis, both of which evaluate its lead small-molecule drug candidate, CardiolRx™.
Investors following CRDL news can expect detailed coverage of clinical milestones such as database lock, topline results, and comprehensive data presentations from randomized, double-blind, placebo-controlled trials. Recent releases describe notable improvements in cardiac magnetic resonance imaging measures in acute myocarditis and progress in the pivotal Phase III MAVERIC trial, which focuses on preventing recurrent pericarditis episodes and reducing symptoms like chest pain and inflammation.
Company news also reports on regulatory and strategic developments, including Orphan Drug Designation for CardiolRx™ in pericarditis, Investigational New Drug authorizations, and intellectual property advances. For example, Cardiol has announced a U.S. patent allowance for cannabidiol compositions for treating heart conditions, expected to protect the use of CardiolRx™ and CRD-38 across a range of cardiac disorders into late 2040.
Additional news items cover financings that support the company’s clinical programs and extend its operating runway, as well as participation in scientific and investor conferences where management discusses trial data and development plans. This news page aggregates these updates so readers can monitor Cardiol Therapeutics’ ongoing clinical results, regulatory milestones, financing activities, and pipeline progress in inflammatory heart disease.
Cardiol Therapeutics (NASDAQ: CRDL) entered a bought deal private placement to issue 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million, with an underwriter option to sell up to an additional 1,038,462 units to raise up to $1.35 million. Each unit includes one common share and one-half warrant; each full warrant exercisable at $1.75 for 24 months.
The offering is expected to close on or about January 23, 2026, is subject to TSX approvals and customary conditions, and the company intends to use net proceeds to advance research and clinical development and for general corporate purposes.
Cardiol Therapeutics (NASDAQ: CRDL) announced it has surpassed 50% patient enrollment in MAVERIC, its pivotal Phase III randomized, double-blind, placebo-controlled trial of CardiolRx for recurrent pericarditis. More than 15 U.S. cardiovascular centers are actively enrolling, with additional sites in Europe and Canada being activated. MAVERIC plans ~110 patients across ~25 centers, a primary endpoint of freedom from new recurrent pericarditis at 6 months, and secondary endpoints including pericarditis pain days, pain score changes, and CRP. Full enrollment is expected in Q2 2026.
Cardiol Therapeutics (NASDAQ: CRDL) reported Phase II ARCHER results showing CardiolRx™ produced structural heart improvements in acute myocarditis after 12 weeks.
Key measured effects included a -9.2 g reduction in left ventricular (LV) mass versus placebo (p=0.0117) and a -8.1 mL reduction in left atrial end systolic volume (p=0.0376). Other CMR endpoints changed numerically but did not reach conventional statistical significance. Safety was reported as balanced between groups.
Cardiol Therapeutics (NASDAQ: CRDL) received a U.S. Notice of Allowance for a patent titled "Cannabidiol Compositions for Use in Treating Heart Conditions", which upon issuance will protect use of CardiolRx and CRD-38 for a broad range of cardiac disorders through October 2040.
The allowance expands the company's global IP portfolio alongside granted and pending patents in Europe, Japan, Canada, Australia, and China, and complements its U.S. Orphan Drug Designation for pericarditis. Management said the allowance supports late-stage programs in recurrent pericarditis and acute myocarditis and upcoming first-in-human evaluation of CRD-38. The company plans to present ARCHER topline data on November 29, 2025, and will update on Phase III MAVERIC enrollment progress.
Cardiol Therapeutics (NASDAQ: CRDL) announced that full Phase II ARCHER trial data for CardiolRx will be presented on November 29, 2025 at the ESC Working Group on Myocardial & Pericardial Disease meeting in Trieste, Italy. Topline results reported improvements in extracellular volume and a significant reduction in left ventricular mass after twelve weeks of blinded therapy in acute myocarditis patients with preserved LV function.
The randomized, double-blind, placebo-controlled ARCHER trial enrolled 109 patients across the US, France, Brazil, and Israel. Cardiol will host a webcast and conference call on December 1, 2025 to discuss findings and next steps.
Cardiol Therapeutics (NASDAQ: CRDL) completed a private placement of 11.4 million units for US$11.4 million on October 21, 2025, funding operations into Q3 2027. Each unit = one common share plus one-half warrant; whole warrants exercise at US$1.35 for 24 months with an acceleration clause if VWAP > US$2.00 for five consecutive trading days. Proceeds fully fund the pivotal MAVERIC Phase III trial and advance CRD-38 through clinical development. New ARCHER trial data showing meaningful LV mass reduction will be presented at a November 2025 cardiology conference. Certain insiders participated under MI 61-101 exemptions.
Cardiol Therapeutics (NASDAQ: CRDL) completed a private placement for net proceeds of US$11 million (11 million Units at US$1.00), with US$10 million closed and US$1 million expected to close on Oct 20, 2025. Proceeds are anticipated to support operations into Q3 2027. Each Unit includes one common share and one-half warrant; whole warrants exercisable at US$1.35 for 24 months with an acceleration clause if shares exceed US$2.00 for five straight days.
The company says its pivotal MAVERIC Phase III program for CardiolRx is fully funded through a planned FDA NDA submission. New ARCHER trial data showed a significant reduction in LV mass, and next‑generation CRD‑38 is funded through clinical development with partnership discussions advancing.
Cardiol Therapeutics (NASDAQ: CRDL), a clinical-stage life sciences company developing treatments for heart disease, will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference. The event will take place in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT.
Investors can access the live webcast through the company's website, with a replay available for 90 days after the conference.
Cardiol Therapeutics (NASDAQ: CRDL) has announced topline results from its Phase II ARCHER trial evaluating CardiolRx™ in acute myocarditis. The trial demonstrated a notable improvement in left ventricular extracellular volume (p = 0.0538) compared to placebo after 12 weeks of treatment.
The study, which enrolled 109 patients across research centers in the US, France, Brazil, and Israel, showed improvements in multiple cardiac magnetic resonance imaging endpoints, including a significant reduction in left ventricular mass. CardiolRx™ maintained a favorable safety and tolerability profile, consistent with findings from the Phase II MAvERIC trial in recurrent pericarditis.
These results provide clinical proof of concept for CardiolRx™ and support advancing its development for cardiomyopathies, heart failure, and myocarditis. The findings will be submitted for presentation at an upcoming scientific meeting and publication.
Cardiol Therapeutics (NASDAQ: CRDL) has announced the database lock for its Phase II ARCHER trial investigating CardiolRx™ in acute myocarditis patients. The trial, which enrolled over 100 patients across research centers in the United States, France, Brazil, and Israel, is a multi-national, randomized, double-blind, placebo-controlled study.
The study's primary outcome measures evaluate cardiac magnetic resonance imaging parameters after 12 weeks of therapy, focusing on global longitudinal strain and extra-cellular volume. These parameters are crucial prognostic markers for myocarditis patients. Topline results are expected within two weeks of the database lock.
Notably, acute myocarditis currently has no FDA-approved drug therapies. The condition results in an average seven-day hospital stay with 4-6% in-hospital mortality risk, costing approximately $110,000 per stay in the United States.
FAQ
What is the current stock price of Cardiol Therapeu (CRDL)?
What is the market cap of Cardiol Therapeu (CRDL)?
